Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
23 December 2022 - 02:36AM
via NewMediaWire -- Aclarion,
Inc.,
(“Aclarion” or the “Company”) (Nasdaq:
ACON, ACONW), a healthcare technology company that is
leveraging biomarkers and proprietary augmented intelligence
algorithms to help physicians identify the location of chronic low
back pain, announced today that Dr. Christopher Ames, Director
of Spinal Deformity and Spine Tumor Surgery and Co-Director of the
Combined High Risk Spine Service, the Neurospinal Disorders
Program, and the UCSF Spine Center at the University of
California at San Francisco will advise the company as a Key
Opinion Leader (KOL) nationally.
Chronic low back pain (cLBP) is a leading
cause of opioid addiction in the U.S. and the single most expensive
diagnosis in the United States. Aclarion’s Nociscan
solution is the first evidence-supported SaaS platform to
noninvasively help physicians distinguish between painful and
nonpainful discs in the lumbar spine. Nociscan objectively
quantifies chemical biomarkers demonstrated to be associated with
disc pain. Biomarker data is entered into proprietary algorithms to
highlight if a disc may be a source of pain. When used with other
diagnostic tools, Nociscan provides critical insights into the
location of a patient’s low back pain, giving physicians clarity to
optimize treatment strategies.Dr. Ames is joining the effort to
bring greater clarity to the diagnosis of chronic low back pain
through the Aclarion KOL program. “Diagnosing pain has
been a conundrum in the treatment of spinal disorders for decades.
A decision support tool like Nociscan will be an important addition
to better understanding spinal disorders and should enhance
physicians’ diagnosis, which will directly impact patient
outcomes,” stated Dr. Ames. “Leveraging innovations like Nociscan
to objectively measure pain biomarkers is a dramatic step forward
in the evolution of understanding and treating chronic low back
pain.”"Aclarion is advancing the intersection between data and
healthcare addressing the costly disabling condition of chronic low
back pain (cLBP). Dr. Ames is one of the foremost thinkers
translating data driven applications to real patient care,” said
Brent Ness, CEO of Aclarion. “We are thrilled to have him on
our KOL team and look forward to his many contributions that we
expect will drastically improve Nociscan and its clinical
application."In addition to previously published clinical evidence,
Aclarion recently announced inclusion of Nociscan in the pivotal
National Institutes of Health funded trial, Biomarkers for the
Evaluation of Spine Treatments, which will include two hundred
patients across seven leading academic teaching institutions in the
United States. Also, in December 2022, Aclarion announced the
addition of a new patent to address anaerobic bacteria that can
seed into the intervertebral disc, proliferate, and accelerate
painful disc degeneration. Collectively, these prior and
current initiatives illustrate the importance of Aclarion’s
disruptive innovation to the spine industry.About Aclarion,
Inc.Aclarion is a healthcare technology company that
leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary
signal processing techniques, biomarkers, and augmented
intelligence algorithms to optimize clinical treatments. The
Company is first addressing the chronic low back pain market with
Nociscan, the first, evidence-supported, SaaS platform to
noninvasively help physicians distinguish between painful and
nonpainful discs in the lumbar spine. Through a cloud connection,
Nociscan receives magnetic resonance spectroscopy (MRS) data from
an MRI machine for each lumbar disc being evaluated. In the cloud,
proprietary signal processing techniques extract and quantify
chemical biomarkers demonstrated to be associated with disc pain.
Biomarker data is entered into proprietary algorithms to indicate
if a disc may be a source of pain. When used with other diagnostic
tools, Nociscan provides critical insights into the location of a
patient’s low back pain, giving physicians clarity to optimize
treatment strategies. For more information, please
visit www.aclarion.com. Forward Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 about the
Company's current expectations about future results, performance,
prospects and opportunities. Statements that are not historical
facts, such as "anticipates," "believes" and "expects" or similar
expressions, are forward-looking statements. These forward-looking
statements are based on the current plans and expectations of
management and are subject to a number of uncertainties and risks
that could significantly affect the Company's current plans and
expectations, as well as future results of operations and financial
condition. These and other risks and uncertainties are discussed
more fully in our filings with the Securities and Exchange
Commission. Readers are encouraged to review the section titled
"Risk Factors" in the Company's Prospectus dated April 21, 2022, as
filed with the Securities and Exchange Commission on April 25, 2022
under Rule 424(b)(4), as well as other disclosures contained in the
Prospectus and subsequent filings made with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contacts:Kirin M.
SmithPCG Advisory, Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG
Consulting612.812.7477jodi@sprigconsulting.com
Aclarion (NASDAQ:ACONW)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aclarion (NASDAQ:ACONW)
Historical Stock Chart
From Mar 2023 to Mar 2024